IL102916A - Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies - Google Patents

Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies

Info

Publication number
IL102916A
IL102916A IL10291692A IL10291692A IL102916A IL 102916 A IL102916 A IL 102916A IL 10291692 A IL10291692 A IL 10291692A IL 10291692 A IL10291692 A IL 10291692A IL 102916 A IL102916 A IL 102916A
Authority
IL
Israel
Prior art keywords
group
carbon atoms
hydrogen
alkyl
antigen
Prior art date
Application number
IL10291692A
Other languages
English (en)
Hebrew (he)
Other versions
IL102916A0 (en
Original Assignee
Alberta Res Council
Integris Baptist Med Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alberta Res Council, Integris Baptist Med Center Inc filed Critical Alberta Res Council
Priority to IL12045392A priority Critical patent/IL120453A/en
Publication of IL102916A0 publication Critical patent/IL102916A0/xx
Priority to IL12045397A priority patent/IL120453A0/xx
Publication of IL102916A publication Critical patent/IL102916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Anesthesiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL10291692A 1991-08-23 1992-08-23 Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies IL102916A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12045392A IL120453A (en) 1991-08-23 1992-08-23 Anti-rejection drug-mediated drug of foreign implant rejection
IL12045397A IL120453A0 (en) 1991-08-23 1997-03-14 Composition for attenuating antibody-mediated xenograft rejection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74952991A 1991-08-23 1991-08-23

Publications (2)

Publication Number Publication Date
IL102916A0 IL102916A0 (en) 1993-01-31
IL102916A true IL102916A (en) 1999-03-12

Family

ID=25014128

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10291692A IL102916A (en) 1991-08-23 1992-08-23 Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies

Country Status (8)

Country Link
US (4) US5651968A (de)
EP (1) EP0661980B1 (de)
JP (1) JP3201523B2 (de)
AT (1) ATE232730T1 (de)
AU (1) AU666128B2 (de)
DE (1) DE69232928D1 (de)
IL (1) IL102916A (de)
WO (1) WO1993003735A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759763A4 (de) * 1994-05-13 1997-07-30 Baxter Int Vermeidung der hyperakuten abstossung von organtransplantaten von schwein zum primaten
US5785966A (en) * 1994-06-15 1998-07-28 Coles; John G. Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
US20040047865A1 (en) * 1995-08-31 2004-03-11 Warner Richard Gareth Compositions and their uses
EP0775493A3 (de) * 1995-11-22 1998-08-12 Baxter International Inc. Extrakorporeale xenogene Organperfusion nach Antikörper-Verringerung durch Immunoapherese
US6444655B1 (en) * 1995-12-21 2002-09-03 Procur Ab Galactopyranosides and their use
WO2001058510A1 (en) * 2000-02-08 2001-08-16 Glycorex Transplantation Ab Oligosaccharide supports for e.g. removal of antibodies from blood
US7014049B2 (en) 1996-12-23 2006-03-21 Glycorex Transplantation Ab Device for bio-affinity material
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
DE69835201T2 (de) 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
AU761831B2 (en) * 1998-04-15 2003-06-12 Bioscience 2002 Llc Inhibition of xenoreactive antibodies
ATE219693T1 (de) 1998-04-27 2002-07-15 Surmodics Inc Bioaktive wirkstoffe freisetzende beschichtungen
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
WO2000033887A2 (en) * 1998-12-08 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
AU2408700A (en) * 1999-01-11 2000-08-01 Baxter International Inc. Method and apparatus for selectively removing xenoreactive antibodies from blood, serum or plasma
ATE474590T1 (de) * 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
HUP0204225A2 (en) * 2000-01-13 2003-05-28 Alchemia Pty Ltd Methods for synthesis and use of alpha-d-gal(1->3)gal-containing oligosaccharides
DE10036742A1 (de) * 2000-07-27 2002-02-21 Aesku Lab Diagnostika Vorrichtung zur Behandlung von Immunerkrankungen
FI20011403A (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
WO2005099786A1 (en) 2004-04-06 2005-10-27 Surmodics, Inc. Coating compositions for bioactive agents
DK1949915T3 (da) * 2004-04-30 2012-11-26 Biopheresis Technologies Inc Fremgangsmåde og system til fjernelse af opløselig TNFR1, TNRF2 og IL2R i patienter
EP1802349A1 (de) * 2004-10-13 2007-07-04 Ilypsa, Inc. Pharmazeutische zusammensetzungen mit einem toxin-bindenden oligosaccharid und einem polymerteilchen
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US9045516B2 (en) 2007-04-16 2015-06-02 Suri Saranathan Iyer Synthetic ligands for the differentiation of closely related toxins and pathogens
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
EP2698636A1 (de) 2012-08-13 2014-02-19 Fundació Institut d'Investigació Biomèdica de Bellvitge Verfahren und Reagenzien zur Vorbeugung und/oder Behandlung von Transplantatabstoßung
WO2014210397A1 (en) * 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
CA2940579A1 (en) 2014-03-13 2015-09-17 Universitaet Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
EP3350193B1 (de) 2015-09-16 2020-12-23 Universität Basel An antikörper gegen glycoepitope von glycosphingolipiden bindende kohlenhydratliganden
CN110699328B (zh) * 2019-08-21 2022-07-19 山东省滨州畜牧兽医研究院 一种b型猪肠道病毒及其应用
CN114920788B (zh) * 2022-05-30 2024-07-30 天津科技大学 人乳三糖半乳糖基乳糖的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5240601A (en) * 1988-11-09 1993-08-31 Chembiomed, Ltd. Affinity supports for hemoperfusion
US5149425A (en) * 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion

Also Published As

Publication number Publication date
AU666128B2 (en) 1996-02-01
EP0661980B1 (de) 2003-02-19
WO1993003735A1 (en) 1993-03-04
IL102916A0 (en) 1993-01-31
JPH07501237A (ja) 1995-02-09
EP0661980A1 (de) 1995-07-12
AU2505992A (en) 1993-03-16
ATE232730T1 (de) 2003-03-15
US6607723B1 (en) 2003-08-19
US5767093A (en) 1998-06-16
DE69232928D1 (de) 2003-03-27
EP0661980A4 (de) 1994-11-24
US5695759A (en) 1997-12-09
JP3201523B2 (ja) 2001-08-20
US5651968A (en) 1997-07-29

Similar Documents

Publication Publication Date Title
EP0661980B1 (de) Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
Baquerizo et al. CHARACTERIZATION OF HUMAN XENOREACTIVE ANTIBODIES IN LIVER FAILURE PATIENTS EXPOSED TO PIG HEPATOCYTES AFTER BIOARTIFICIAL LIVER TREATMENT: An Ex Vivo Model of Pig to Human Xenotransplantation: 1, 2
Pilatte et al. Sialic acids as important molecules in the regulation of the immune system: pathophysiological implications of sialidases in immunity
Cooper et al. Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man
NEETHLING et al. PROTECTION OF PIG KIDNEY (PK15) CELLS FROM THE CYTOTOXIC EFFECT OF ANTI-PIG ANTIBODIES BY α-GALACTOSYL OLIGOSACCHARIDES1
Holgersson et al. Characteristics of protein–carbohydrate interactions as a basis for developing novel carbohydrate‐based antirejection therapies
Garratty Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs
Nyame et al. Schistosoma mansoniInfection in Humans and Primates Induces Cytolytic Antibodies to Surface LexDeterminants on Myeloid Cells
Garratty Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion
Allison et al. Effects of endotoxin on macrophages and other lymphoreticular cells
US5977079A (en) Compositions for attenuating antibody- mediated xenograft rejection in human recipients
Handman et al. Carbohydrate antigens as possible parasite vaccines
Spitalnik et al. Anti-My-28, an antigranulocyte mouse monoclonal antibody, binds to a sugar sequence in lacto-N-neotetraose
Zhu BINDING OF HUMAN NATURAL ANTIBODIES TO NONαGal XENOANTIGENS ON PORCINE ERYTHROCYTES1
Rydberg et al. Studies on the removal of anti‐pig xenoantibodies in the human by plasmapheresis/immunoadsorption
Rydberg et al. α-Gal epitopes in animal tissue glycoproteins and glycolipids
CA2116138C (en) Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
Brondz et al. Enrichment of effector T lymphocytes specific to H‐2 antigens by elution from allogeneic target cells and characterization of the eluted lymphocyte population
JPH07504222A (ja) 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
JP2001518074A (ja) Ｂ細胞の免疫寛容誘導
IL120453A (en) Anti-rejection drug-mediated drug of foreign implant rejection
Kyoizumi et al. A lectinlike receptor on murine macrophage cell line cells, Mm1: involvement of sialic acid-binding sites in opsonin-independent phagocytosis for xenogeneic red cells
EP0847280B1 (de) Zusammensetzungen und ihre anwendungen gegen die hyperakute abstossung von transplantaten und bestimmte krankheiten
US20040047865A1 (en) Compositions and their uses
WO2023172180A1 (en) New use of peg-phospholipid molecules

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees